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INTRODUCTION
In their opening brief the minority shareholders stressed two fundamental errors
committed by the District Court. First, the District Court rejected all evidence of how
the stock market would have valued Zinetics shares on the valuation data for reasons
inconsistent with the governing statute and other applicable state law. Certainly, the
District Court is invested in this equitable proceeding to consider the weight, if any, to
be given to the evidence but those decisions must be consistent with applicable law.
The valuation data applicable to this decision was February 12, 1998, during the most
robust stock market of the last twenty years. The Court's rejection of ail market-based
evidence deprived the minority shareholders of the value of their shares in such a
market. The Court's conclusion that market based values would "fluctuate inexplicably
overtime in a manner unrelated to the fundamental financial performance of the
companies," even if it had been supported by the record, which if hod not, is irrelevant.
In a free market, financial ratios of groups of companies do vary widely over
time. If this were not true, markets would be largely static and there would be no need
to perform data specific analysis. Critically, the controlling statute Utah Code. Ann. §
16-1 Oa-1301 (u) requires synchronic analysis. In light of the statutory requirements, the
Court erred in rejecting the market analysis proffered by the minority shareholders.
The District Court's other reason for rejecting market valuation methodology is
that the methodology "has not been recognized as a valuation tool by our courts." That
conclusion is simply wrong.
Finally, Medtronic's attempt to bootstrap an evidentiary basis tor the Court's
conclusion that the fair value of the shares was less than that imposed on the minority
F:\USERS\CMW\Hogle\Plead\reply.brief2.wpd
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shareholders in the freeze-out merger cannot withstand scrutiny. As demonstrated
below and in the minority shareholders' opening brief, the Court failed to adequately
support its conclusion that the minority shareholders received the fair value of their
shares.
I.

THE MINORITY SHAREHOLDERS DID NOT RECEIVE FAIR VALUE FOR
THEIR STOCK BECAUSE OF THE REFUSAL OF THE DISTRICT COURT
REFUSED TO CONSIDER ANY STOCK MARKET VALUATION
INFORMATION
The minority shareholders in this proceeding own shares of stock in Zinetics.

The minority shareholders did not own an apartment building, an annuity, or the right to
receive income. They owned freely trading shares of stock for which many had paid
between ten and seventeen cents per share. See Appellants' Br. at 4. They had the
right to receive fair value for their stock and to have that value determined the way
value for shares of stock is typically determined - by examining market data. The sum
total of all available market information is what the Court below should have used to
determine the value of the minority shareholders' investment in these shares. However,
the District Court failed to consider any relevant market information.
The parties provided the District Court with a great deal of evidence as to how
the market valued shares of other similar companies on or about the valuation date.
That testimony came from Mr. Reilly, the shareholders themselves, and Mr. Norman.
All of this information led ineluctably to the conclusion that the shares had a higher fair
value than that imposed by Medtronic in its freeze-out merger.
The minority shareholders presented evidence of market valuation of the Zinetic
stock that was offered by a respected expert, Robert Reilly. The methodology was

F:\USERS\CMW\Hogle\Plead\reply.brief2.wpd
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consistent with long accepted valuation techniques and described by Mr. Reilly in his
book Valuing a Business: The Analysis and Approval of Closely Held Companies.
In the period prior to the merger, shares of Zinetics had traded between 10 and
17 cents per share. Mr. Reilly and Mr. Norman did not use that information in
calculating a value, because of the thinness of the market for Zinetics' stock.
Nonetheless, that hardly means that the District Court should totally disregard such
information, particularly when the information is not inconsistent with other market data.
As is nearly always the case, there was no company that was so nearly identical
to Zinetics that it could be used as a "comparable," as that term is typically used in real
estate valuation. Instead, Mr. Reilly identified an array of companies that were the most
similar to Zinetics and that also were publically reporting companies so that adequate
information could be obtained to calculate the fair value of Zinetics shares. Such
companies are typically referred to by valuation experts, such as Mr. Reilly, as
"guideline companies."
A.

The Guideline Companies Were Not Dissimilar to Zinetics

Medtronic suggests that the companies selected by Mr. Reilly as guideline
companies were dissimilar to Zinetics. See Appellees' Br. at 22. That is demonstrably
false. Mr. Reilly, in his testimony, enumerated the factors that he used to select
guideline companies. First, he started by selecting companies with SIC Code 3841.
SIC 3841 is the standard industry code for companies that manufacture medical
products. Then he used a size similarity factor, selecting companies by imposing the
requirement that the companies be within an order of magnitude of Zinetics in sales,
which is to say that they were neither ten times smaller nor ten times larger than
F:\USERS\CMW\Hogle\Plead\reply.brief2.wpd
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Zinetics. Third, the companies had to be domestic companies with actively traded stock
and should be traded either OTC or on NASDAQ. Fourth, the companies had to have
material revenues which means that they were actually producing and selling products.
In fact, the guideline companies selected by Mr. Reilly were growing at about the same
pace as Zinetics. The companies were past the development stage because they had
successfully commercialized some of their products, and, finally, they all produced
catheters. See Tr. at 503-10.
Mr. Reilly then applied all these criteria, which Mr. Norman admitted were proper
(Tr. 733), to a data base of over 11,000 companies, and used all of the companies that
met them. That selection process produced 11 companies. He used the median of that
array of companies as the best measure of central tendency.
The District Court, in its opinion, rejected the market information this
methodology produced, saying that Mr. Reilly made no adjustment for "structural and
performance differences." See Mem. Dec. at 13. With respect to "structural" issues,
there was no evidence that there is anything structurally dissimilar in comparing the
guideline companies to Zinetics. They all manufacture catheters, they are all of
approximately the same size, they are all in production and producing revenues, and
there was no testimony that any of them had unusual capital structures that would have
somehow made them "structurally" different.
With respect to performance differences, the only difference argued by Medtronic
was that Zinetics was more successful than the other companies because it had higher
earnings, even though similar revenues. Generally speaking, companies that are more
profitable are worth more on the stock market, not less. Thus, the District Court and
F:\USERS\CMW\Hogle\Plead\reply.brief2.wpd
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Medtronic appear to be criticizing the use of the guideline companies on the grounds
that the pricing information available by reference to these guideline companies was not
adjusted upward by Mr. Reilly. Had Mr. Reilly made adjustments in the way the market
itself values these companies, he would increase by adjustment the value of Zinetics.
As explained above, Mr. Reilly selected his guideline companies by applying
neutral criteria to a database of over 11,000 companies to select those that most
closely mirror Zinetics. Thus, Medtronic's suggestion that those guideline companies
are dissimilar to Zinetics is simply not true.
B.

There Was No Expert Testimony Offered Supporting The Conclusion
That "Adjustments" Should Be Made To A Valuation Methodology
Using Guideline Companies

Medtronic provided no testimony that adjustments should be made to valuations
derived from guideline company methodology that Mr. Reilly employed. Had Mr. Reilly
made such adjustments, he would not be using information directly from the market but
making adjustments to it and thus imposing his own subjective opinion on the objective
process. One can safely assume that had Mr. Reilly adjusted the price upward to
account for the comparative profitability of Zinetics to the other small, catheterproducing companies, Medtronic would have criticized him for doing so and, likewise,
would have urged the Court to reject such information on the grounds that Mr. Reilly
improperly adjusted market information. In fact, there was no "adjustment" proposed to
the market-derived valuation of Mr. Reilly. Rather, the District Court was simply urged
to reject it entirely.
There is an obvious reason for this, and one only need look at Mr. Norman's own
testimony to understand Medtronic's motivation. Mr. Norman also purported to value
F:\USERS\CMW\Hogle\Plead\reply.brief2.wpd
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Zinetics based upon market information. However, instead of applying neutral criteria
to the entire database of companies, Mr. Norman selected huge, multi-national medical
companies as his guideline companies. Mr. Norman then derived price earnings ratios
from these companies. He testified that using price earning ratios is a much better way
of valuing companies than a market capitalization to revenue ratio. Having obtained
those price earnings ratios, Mr. Norman was then forced to adjust them by nearly half in
order to bring his valuation within that imposed by Medtronic in the freeze-out merger.
Interestingly, however, Mr. Reilly testified that smaller companies tend to have
larger PE ratios than bigger companies. See Tr. at 573. Mr. Norman did not counter
this testimony at all. Thus, Mr. Norman apparently made an adjustment that is directly
inverse to how the market actually works. If Mr. Norman had only used the price
earnings ratios that he had determined and applied it to the earnings of Zinetics, a
valuation of approximately $ .09/share would result.1 This would undervalue Zinetics
because of size disparity.
As the testimony also demonstrated, Zinetics was consolidated for financial
purposes with Medtronic. Medtronic traded at more than 50 to 1 price-to-eamings ratio.
See Appellants' Br. at 18. Thus, the market valued each dollar of earnings of Zinetics
prior to and subsequent to the freeze-out merger at an approximately 50-1
price/earnings ratio, to the benefit of Medtronic's shareholders. In this equitable
proceeding, the District Court should have concluded that this evidence has at least
some probative value.
1

The P/E from Schedule M is 24. Multiply trading earnings of $480,500.00
and divide by number of shares (128,806,800 shares) = 9 cents/share.
F:\USERS\CMW\Hogle\PIead\reply.brief2.wpd
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Medtronic argues that the District Court had unfettered discretion to accept or
reject evidence. The Court's discretion is not unlimited. The Court must exercise that
discretion consistent with the governing statute. The District Court's rejection of market
information by imposing a requirement that financial ratios be consistent over time which they never are - is legal error and requires reversal.
In sum, all of the information available as to how shares of companies similar to
Zinetics actually trade in the market, as well as the information as to the actual trades in
Zinetics, create values for Zinetics of 9 to 25 cents per share. The minority
shareholders were entitled to get the fair value of their shares of stock, not the value of
something else. For the District Court to reject all information that shows what Zinetics
shares actually sold for and what similar shares sell for in the market deprived the
minority shareholders of the "fair value" of their shares to which they were statutorily
entitled.
In conclusion, whatever discretion the District Court had, it did not have the
discretion to reject Mr. Reilly's testimony on grounds inconsistent with the controlling
statute, inconsistent with other applicable law and inconsistent with acceptable
methodology. As a direct result of the District Court's rejection of the market method,
the minority shareholders were deprived of receiving the fair value of their stock on a
date during the most robust stock market in history.
II.

NO SUBSTANTIAL EVIDENCE SUPPORTS THE COURT'S CONCLUSION OF
FAIR VALUE
This equitable proceeding before the Court was to determine the fair value of the

Zinetics shares on February 12, 1998. The Court rejected or ignored all evidence of

F:\USERS\CMW\Hogle\Plead\reply.brief2.wpd
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value other than an income or discounted cash flow methodology, which the Court
denominated 'investment valuation." The Court's ultimate conclusion, stated on page
13 of the Opinion, was:
When the numbers proposed by Respondents for revenue discount rate
and capitalization rate are used to recalculate Mr. Norman's investment
valuations, the results do not exceed the $0.04528 per share offered by
Medtronic for the Respondents' common stock.
Opinion, p. 13. One of the predominant issues in this appeal is whether any substantial
evidence supports that ultimate conclusion.
An examination of the calculation the Court indicated should be used reveals
that the minority shareholders did not receive fair value for their shares. An income or
discounted cash flow valuation is the sum of yearly calculations which are relatively
simple once the numbers to be used are derived. One need only take the projected
revenues and divide by the capitalization rate to determine the yearly valuations which
are then summed to result in a total valuation. The revenue projections are simply an
initial year's projection increased by a set rate.
The numbers "proposed by Respondents" for each of the revenue discount rate
and the capitalization rate may be found in Mr. Reilly's report. See Exs. VIII through XL
With respect to the first year's projected revenues, Mr. Reilly criticized Mr. Norman's
calculations because Mr. Norman viewed a company which had shown incoming
increasing revenues at a compound rate of approximately 23.1 % for a period of five
years and without explanation projected earnings for the first or base year that were
less than the prior year. In other words, Mr. Norman took Zinetic's steadily increasing
earning stream and decreased it without any reasonable explanation. Mr. Reilly did not

F:\USERS\CMW\Hogle\Plead\reply.brief2.wpd
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"propose" that the base year be set at the same level as the preceding year. Instead,
Mr. Reilly followed the trend of Zinetics' earnings and projected a base year higher than
the preceding year.
If the numbers for revenue capitalization rate and inflation rate "proposed by
Respondents" are used, and all other valuation information, including the market
approach and the minority shareholders' offer to purchase are ignored, then the value
of the shares may be obtained by simply calculating the given amounts. As set forth on
page 2 of Ex. XI to Mr. Reilly's report, the average of those three iterations is
$17,283,000. If one divides that number by the number of outstanding shares
(128,806,800) of Zinetics, then one obtains a valuation of $0.1342 per share. That
value is substantially more than the approximately 4 cents per share the minority
shareholders received from Medtronic.
Mr. Norman's calculations, adjusted to use Respondents' proposed numbers, as
the Court stated was appropriate, is the only basis of supporting the Court's conclusion.
Nothing else in the record supports that conclusion. If the District Court's opinion is to
be made internally consistent, and the numbers "proposed by Respondents for revenue
capitalization rate and inflation rate" are used, then the result is that the minority
shareholders should be paid $0.13 per share. Thus, even if every other point raised on
appeal by the minority shareholders is rejected by this Court, in order to make the
Court's opinion internally consistent and adopt the methodology the Court apparently
believed it was using, the judgment should be reversed and the minority shareholders
should be entitled to be paid the difference between $0.04528 and $0.13 per share.

F:\USERS\CMW\Hogle\Plead\reply.brlef2.wpd
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Medtronic attempts to provide the calculations the District Court did not set out in
its opinion. See Appellees' Br. at 15-16. However, the calculations they provide are
inconsistent with the District Court's opinion. Mr. Reilly did not "propose" to add a 10%
increase to Mr. Norman's projections. Rather, he noted that one effect of Mr. Norman's
diminishing earnings from previous years was to lock in a 10% reduction. The
calculations that Medtronic offers appear no where in the record, and neither the
minority shareholders nor Mr. Reilly proposed such calculations. They are simply an
attempt to provide support for the District Court's conclusion when none exists in the
record.
An entire calculation on a year by year basis, including both increases and
discounting, would be necessary in order to provide the true numbers that Mr. Reilly
proposed on behalf of the minority shareholders. Fortunately, those numbers appear in
Mr. Reilly's report and the results are as indicated above.
Medtronic purports to cite support in the record for the conclusions of the District
Court. See Appellees' Br. at Add. 4. The most important of these is the purported
support on page 13 for the District Court's statement that "when the numbers proposed
by Medtronic for revenue, discount rate and capitalization rate are used to recalculation
[sic] Mr. Norman's investment evaluations, the results do not exceed the 0.04528 per
share offered by Medtronic for the Respondents' stock." As evidence, Medtronic cites
to Norman testimony at trial, pp. 731-32 and Norman Report Schedules A, F., G. I, and
J. These references do not support the court's opinion. One will not find the numbers
that Medtronic proposes for either revenue discount rate or capitalization rate in Mr.
Norman's testimony or in his report schedules.
F:\USERS\CMW\Hogle\Plead\reply.bnef2.wpd

10

For instance, Schedules A, F, G, I and J are the original schedules Mr. Norman
offers as part of his valuation report. They are his calculations - not projections Mr.
Reilly offers. The testimony at 731-32 is simply a statement in response to one
criticism. Mr. Reilly had criticized Schedule F - a direct capitalization model - by
pointing out that Mr. Norman had built in a 10% persistent decrease in earnings into
perpetuity. Mr. Reilly neither adopted Mr. Norman's projections nor "proposed" that if
Norman's projections could be corrected by only adding 10% to the base year. Mr.
Reilly only offered this criticism of Mr. Norman's direct capitalization model as an
example of its fundamental deficiencies.
In short, the Court's conclusion that the fair value of the minority shareholders'
Zinetics shares was less than the $0,045 per share that they received from Medtronic
finds no support in the record. Medtronic's valiant attempt to prop up the District
Court's decision falls far short of the mark. This Court should remand this case for an
adequate determination of the fair value of the dissenters' shares.
III.

THE DISTRICT COURT MADE NO FINDING THAT THE MINORITY
SHAREHOLDER'S ATTEMPT TO PURCHASE THE MAJORITY OF THE
SHARES FOR $.10 PER SHARE WAS A "SHAM"
Perhaps the low point in Medtronic's brief is their gratuitous characterizations of

the minority shareholders' final offer to purchase the majority block of shares of Zinetics
as "bogus" and a "sham." See Appellees' Br. at 30-31. The District Court made no
such finding. Rather, the District Court totally ignored this evidence completely. As the
record indicated, the minority shareholders had resources available to make such an
offer. See generally Testimony of Jack Gallivan and Ronald Johnson. Moreover, such
a price was not inconsistent with prices paid many years earlier by these shareholders.
F:\USERS\CMW\Hogle\Plead\reply.bnef2.wpd
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See generally Testimony of P. Hogle and J. Gallivan. For Medtronic to accuse the
Gallivans, Hogles and others of engaging in a sham with no such finding by the District
Court is shameful.
CONCLUSION
Because of the District Court's errors, the minority shareholders were deprived of
recovery of the fair value of their shares. They were forced to surrender those shares
to defendants in a freeze-out merger and as a result they should be entitled to fair
value. The best measure of the value is ascertained by determining the financial ratios
at which similar guideline companies sold in efficient stock markets on the valuation
date. The District Court rejected that information for reasons inconsistent with the
governing statute.
The minority shareholders respectfully submit that this Court should reverse the
District Court's decision and either determine a proper valuation based upon market
data or remand to the District Court with instructions to either appoint a special master
or include the guideline company valuation data in its final determination of fair value.
DATED this 28th day of September, 2001.
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